Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
Journal of Nuclear Medicine · 2024-04 · 65 (4) · 580-585
DOI: 10.2967/jnumed.123.266524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.03.2024. Verfasst von Kyeara N Mack und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: CA-125 Antigen, Ovarian Neoplasms, Antibodies, Monoclonal, Humanized, Mucins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a humanized antibody, huAR9.6, targeting fully glycosylated and hypoglycosylated MUC16 isoforms.
Methods
In vitro and in vivo targeting of the diagnostic radiotracer [89Zr]Zr-DFO-huAR9.6 was investigated via binding experiments, immuno-PET imaging, and biodistribution studies on OC mouse models. Ovarian xenografts were used to determine the safety and efficacy of the therapeutic version, [177Lu]Lu-CHX-A″-DTPA-huAR9.6.
Results
In vivo uptake of [89Zr]Zr-DFO-huAR9.6 supported in vitro-determined expression levels: high uptake in OVCAR3 and OVCAR4 tumors, low uptake in OVCAR5 tumors, and no uptake in OVCAR8 tumors. Accordingly, [177Lu]Lu-CHX-A″-DTPA-huAR9.6 displayed strong antitumor effects in the OVCAR3 model and improved overall survival in the OVCAR3 and OVCAR5 models in comparison to the saline control. Hematologic toxicity was transient in both models.
Conclusion
PET imaging of OC xenografts showed that [89Zr]Zr-DFO-huAR9.6 delineated MUC16 expression levels, which correlated with in vitro results. Additionally, we showed that [177Lu]Lu-CHX-A″-DTPA-huAR9.6 displayed strong antitumor effects in highly MUC16-expressing tumors. These findings demonstrate great potential for 89Zr- and 177Lu-labeled huAR9.6 as theranostic tools for the diagnosis and treatment of OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York.
- Department of Chemistry and Biochemistry, California State University, Fresno, California.
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska; and.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; lewisj2@mskcc.org.
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Mack, K. N., Samuels, Z. V., Carter, L. M., Viray, T. D., Mandleywala, K., Brooks, C. L., Hollingsworth, M. A., Radhakrishnan, P., & Lewis, J. S. (2024). Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer. Journal of Nuclear Medicine, 65(4), 580-585. https://doi.org/10.2967/jnumed.123.266524
Vancouver
Mack KN, Samuels ZV, Carter LM, Viray TD, Mandleywala K, Brooks CL, et al. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer. Journal of Nuclear Medicine. 2024;65(4):580-585. doi:10.2967/jnumed.123.266524
BibTeX
@article{Mack2024,
author = {Mack, Kyeara N and Samuels, Zachary V and Carter, Lukas M and Viray, Tara D and Mandleywala, Komal and Brooks, Cory L and Hollingsworth, Michael A and Radhakrishnan, Prakash and Lewis, Jason S},
title = {Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {4},
pages = {580--585},
doi = {10.2967/jnumed.123.266524}
}
EUVIMED